Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

ClinicalTrials.gov ID: NCT03717012

Public ClinicalTrials.gov record NCT03717012. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objectives of this study are: * Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine the difference in change in Quality of Life (QoL) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine if there is an enduring effect in 6MWD, QoL and lung function from pulmonary rehabilitation (PR) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF)

Study identification

NCT ID
NCT03717012
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
19 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2018
Primary completion
Mar 26, 2020
Completion
Jun 9, 2020
Last update posted
Jun 8, 2021

2018 – 2020

United States locations

U.S. sites
19
U.S. states
16
U.S. cities
19
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294
Loma Linda University Medical Center Loma Linda California 92354
Western Connecticut Medical Group Danbury Connecticut 06810
Miami VA Healthcare System Miami Florida 33125
Coastal Pulmonary & Crit Care St. Petersburg Florida 33704
The LaPorte County Institute for Clinical Research Michigan City Indiana 46360
Pulmonary and Critical Care Associates of Baltimore Towson Maryland 21286
University of Michigan Health System Ann Arbor Michigan 48109
St. Vincent Physicians Sleep and Respiratory Center Billings Montana 59101
Glacier View Research Institute Kalispell Montana 59901
Icahn School of Medicine at Mount Sinai New York New York 10029
Pulmonix, LLC Greensboro North Carolina 27403
Temple University Hospital Oaks Pennsylvania 19456
Vanderbilt University Medical Center Nashville Tennessee 37232
Baylor University Medical Center Dallas Texas 75246
Metroplex Pul and Sleep Ctr McKinney Texas 75069-1769
University of Virginia Health System Charlottesville Virginia 22903
Providence Sacred Heart Medical Center and Children's Hospital Spokane Washington 99204
Froedtert and The Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03717012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 8, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03717012 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →